CA2915882C - Il-21 binding proteins and uses thereof - Google Patents

Il-21 binding proteins and uses thereof Download PDF

Info

Publication number
CA2915882C
CA2915882C CA2915882A CA2915882A CA2915882C CA 2915882 C CA2915882 C CA 2915882C CA 2915882 A CA2915882 A CA 2915882A CA 2915882 A CA2915882 A CA 2915882A CA 2915882 C CA2915882 C CA 2915882C
Authority
CA
Canada
Prior art keywords
binding protein
protein
antibody
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2915882A
Other languages
English (en)
French (fr)
Other versions
CA2915882A1 (en
Inventor
Charles Reay Mackay
Di YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902377A external-priority patent/AU2013902377A0/en
Application filed by Monash University filed Critical Monash University
Publication of CA2915882A1 publication Critical patent/CA2915882A1/en
Application granted granted Critical
Publication of CA2915882C publication Critical patent/CA2915882C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2915882A 2013-06-27 2014-06-27 Il-21 binding proteins and uses thereof Active CA2915882C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013902377A AU2013902377A0 (en) 2013-06-27 A super-agonist monoclonal antibody to human IL-21 and its application in immunomodulation
AU2013902377 2013-06-27
PCT/AU2014/000673 WO2014205501A1 (en) 2013-06-27 2014-06-27 Il-21 binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
CA2915882A1 CA2915882A1 (en) 2014-12-31
CA2915882C true CA2915882C (en) 2022-12-06

Family

ID=52140667

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2915882A Active CA2915882C (en) 2013-06-27 2014-06-27 Il-21 binding proteins and uses thereof

Country Status (8)

Country Link
US (3) US10077301B2 (2)
EP (1) EP3013858B1 (2)
JP (1) JP6563389B2 (2)
CN (1) CN105579470B (2)
AU (1) AU2014302028B2 (2)
CA (1) CA2915882C (2)
ES (1) ES2898650T3 (2)
WO (1) WO2014205501A1 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579470B (zh) 2013-06-27 2021-05-25 莫纳什大学 Il-21结合蛋白和其用途
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
EP3404040B1 (en) * 2016-01-12 2022-03-02 National University Corporation Chiba University Anti-myl9 antibody
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN119290543B (zh) * 2024-12-13 2025-03-21 天津医科大学总医院空港医院 一种同时检测淋巴组织中il-6、il-21与t细胞cd4表面分子的试剂盒及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
US8343489B2 (en) 2006-03-21 2013-01-01 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
WO2008112543A2 (en) * 2007-03-09 2008-09-18 Wyeth Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
US20140170153A1 (en) * 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands
CN105579470B (zh) 2013-06-27 2021-05-25 莫纳什大学 Il-21结合蛋白和其用途

Also Published As

Publication number Publication date
JP2016529213A (ja) 2016-09-23
AU2014302028A1 (en) 2016-01-21
US10787510B2 (en) 2020-09-29
US10077301B2 (en) 2018-09-18
WO2014205501A1 (en) 2014-12-31
US20210002362A1 (en) 2021-01-07
AU2014302028B2 (en) 2019-09-19
CA2915882A1 (en) 2014-12-31
ES2898650T3 (es) 2022-03-08
CN105579470B (zh) 2021-05-25
CN105579470A (zh) 2016-05-11
US20190071497A1 (en) 2019-03-07
EP3013858A1 (en) 2016-05-04
EP3013858A4 (en) 2017-01-25
EP3013858B1 (en) 2021-07-28
JP6563389B2 (ja) 2019-08-21
US20160145332A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
JP7727387B2 (ja) 新規の抗ｃｄ３９抗体
JP7043685B2 (ja) ヒト化抗ヒトｐｄ－１抗体
KR102926972B1 (ko) Pd-l1 및 cd137에 결합하는 항체 분자
US10787510B2 (en) Methods of treating cancer using an IL-21 agonist
CN112142847B (zh) 改造的Fc片段，包含其的抗体及其应用
JP7498714B2 (ja) Ｂ型肝炎ウイルスを中和する抗体およびその使用
JP6545105B2 (ja) Ｉｌ−１１ｒ結合タンパク質及びその使用
JP2020063270A (ja) 免疫活性化抗原結合分子
US20210244825A1 (en) Il-21 antibodies
ES2828482T3 (es) Anticuerpos contra el g-csfr y su uso
JP7386877B2 (ja) 新規の抗ｉｆｎａｒ１抗体
US20230416394A1 (en) Novel conjugate molecules targeting cd39 and tgfbeta
JP2024531900A (ja) 新規の抗ｓｉｒｐａ抗体
US20240336686A1 (en) Novel multi-specific molecules
TW202411246A (zh) 經工程化之b型肝炎病毒中和抗體及其用途
TW202334218A (zh) 新型抗ｌａｇ３抗體
HK40041672B (zh) 新型抗cd39抗体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190618

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241227